All News

Your daily dose of the clinical news you may have missed.

Long-term risk of death decreased by 26% and risk for vascular complications decreased by 40% in persons who remained diabetes-free for 4 years, according to new data.

The agency is concerned about manufacturing processes involved in production and about the proposed indication for adults with type 1 diabetes.

Your daily dose of the clinical news you may have missed.

Continuous statin use among adults aged 75 years and older resulted in a mean relative risk reduction in CVD of 28% without heightened safety concerns, a new study found.

Following the statewide order in August 2022, emergency contraceptive fills at Massachusetts pharmacies increased by 32% compared with rates in other states.

The 11-year-old girl has had a fever up to 102.1°F for 3 days and midsternal nonpleuritic chest pain for 1 day. What tests would you order? Your Dx?

A new study shows that higher vaccination rates were associated with a decrease in the prevalence of parent-reported asthma symptoms in children.

Your daily dose of the clinical news you may have missed.

Tirzepatide-treated participants were 3 times more likely than those treated with semaglutide to reach weight loss of 15% or greater, the head-to-head study found.

GLP-1RAs were associated with a significantly reduced risk of obesity-associated cancers including gallbladder cancer, pancreatic cancer, and meningioma.

Your daily dose of the clinical news you may have missed.

Findings from a national survey also showed that Black respondents were most likely to believe they could not receive medications for OUD at a PCP.

Your daily dose of the clinical news you may have missed.

The preserved bone mass observed in participants taking liraglutide and exercising was seen despite weight reduction levels similar to outcomes with semaglutide and tirzepatide.

Donanemab, now 1 of 2 antiamyloid medications available, is unique based on evidence that it can be used in limited duration treatment, based on removal of plaque.

The international statement targets primary care clinicians and endocrinologists with detailed guidance on monitoring disease progression and providing education.

The novel vaccination is recommended as an option for adults aged 65 years and older who have not received a pneumococcal conjugate vaccine.